80 Of GPs Believe Cardiac Arrhythmias To Be Widely Under-recognised And Often Untreated, New Research Shows, UK
Patients with potentially fatal cardiac arrhythmias, an abnormality of the heart's rhythm, are not being diagnosed or treated, according to new research issued today.1 Over 700, 000 people in the UK are affected by an arrhythmia and it is consistently among the top ten causes of hospital admission.
Polypill Reaches Clinical Testing Phase
Two years on from the announcement of its intention to advocate for the development of the polypill for post myocardial infarction (heart attack) patients, the World Heart Federation can report that the polypill has now reached the clinical testing phase.
FDA Grants Approval To Begin Landmark Cardiac Resynchronization Therapy Study, EchoCRT
BIOTRONIK, the pioneer in wireless remote monitoring technologies for patients with implantable cardiac pacemakers and defibrillators, announced the FDA approval to begin an international, prospective, randomized, controlled clinical trial to investigate the use of Cardiac Resynchronization Therapy (CRT) in heart failure (HF) patients with left ventricular systolic dysfunction.
XIENCE V Drug Eluting Stent From Abbott Outperforms Market-Leading Stent In Reducing Major Adverse Cardiac Events At Two Years
Long-term data presented for the first time from the SPIRIT III trial, Abbott's U.S. pivotal trial studying the XIENCE™ V Everolimus Eluting Coronary Stent System, demonstrated that XIENCE V continues to deliver clinically superior benefits for patients compared to the TAXUS paclitaxel-eluting coronary stent system.
Patients With Heart-Lung Disease May Benefit From Cancer Drug
A drug developed to fight cancer is showing early promise as a treatment for pulmonary hypertension, researchers from the University of Chicago Medical Center reported May 19 at the American Thoracic Society International Conference in Toronto, Canada.
Abbott Launches Next-Generation StarClose reg; SE Vascular Closure System
Abbott announced the launch of the StarClose SE Vascular Closure System, a next-generation vessel closure device engineered to enable fast, safe and secure closure of the femoral artery access site following a catheterization procedure. StarClose SE is available in the United States and Europe.
News From The Journal Of Clinical Investigation, May 15, 2008
Genetic mutation causes seizures and an irregular heartbeatExercise or becoming highly emotional can cause the heartbeat to become irregular, often causing sudden death, in individuals with an inherited heart disorder known as catecholaminergic polymorphic ventricular tachycardia (CPVT).
XIENCE TM V Drug Eluting Stent From Abbott Reduces Major Adverse Cardiac Events In Small Vessel Patients Out To One Year
Data presented from an independent pooled subset analysis of Abbott's SPIRIT II and SPIRIT III clinical trials demonstrated a clinically significant 51 percent reduction in major adverse cardiac events (MACE) with the XIENCE™ V Everolimus Eluting Coronary Stent System compared to the TAXUS paclitaxel-eluting coronary stent system in patients with small vessels out to one year.
Landmark ATHENA Study Findings With Multaq R Show 24 Reduction In Cardiovascular Hospitalisation Or Death In Patients With Atrial Fibrillation
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that findings from the landmark ATHENA study showed that Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalisations or death from any cause by a statistically significant 24% (p=0.
LifeWatch Corp. Launches First To Market Atrial Fibrillation Patient Care Program
LifeWatch announced that it has launched the first-to-market AF (Atrial Fibrillation) Patient Care Program for monitoring patients across the nation. Following successful pilots at leading academic institutions, LifeWatch has now expanded its customized patient care program for the untapped market of periop-monitoring of those patients undergoing AF catheter and surgical ablation procedures.